SCHEMBL1044166

SCHEMBL1044166

NC(=O)C12CC3CC(C1)C(NC(=O)OCc1ccccc1)C(C3)C2

nearest known ligand 0.57

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 15/20 0.57
HSD11B2 P80365 3/20 0.57
TSHR P16473 1/20 0.49
EPHX2 P34913 1/20 0.48
CPB1 P15086 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1844036 1.00 HSD11B1 (0.57) HSD11B1HSD11B2TSHREPHX2CPB1
SCHEMBL1844038 1.00 HSD11B1 (0.57) HSD11B1HSD11B2TSHREPHX2CPB1
SCHEMBL1844035 1.00 HSD11B1 (0.57) HSD11B1HSD11B2TSHREPHX2CPB1
SCHEMBL1846641 0.91 HSD11B1 (0.56) HSD11B1HSD11B2TSHREPHX2CPB1
SCHEMBL1846642 0.91 HSD11B1 (0.56) HSD11B1HSD11B2TSHREPHX2CPB1
SCHEMBL2825063 0.91 HSD11B1 (0.56) HSD11B1HSD11B2TSHREPHX2CPB1
SCHEMBL12578487 0.91 HSD11B1 (0.56) HSD11B1HSD11B2TSHREPHX2CPB1
SCHEMBL1845687 0.91 HSD11B1 (0.56) HSD11B1HSD11B2TSHREPHX2CPB1
SCHEMBL2837021 0.87 CPB1 (0.49) HSD11B1HSD11B2EPHX2CPB1
SCHEMBL1844608 0.87 CPB1 (0.49) HSD11B1HSD11B2EPHX2CPB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103242192-B The inhibitor of 11-beta-hydroxysteroid dehydrogenase 1 type enzyme ABBVIE INC. (US) 2016-05-04 CN disclosed
EP-2269977-B1 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme ABBVIE INC (US) 2016-04-27 EP disclosed
US-9290444-B2 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme ABBVIE INC. (US) 2016-03-22 US disclosed
US-20150065508-A1 INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME ABBVIE INC. (US) 2015-03-05 US disclosed
US-8716345-B2 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme ABBVIE INC. (US) 2014-05-06 US disclosed
US-20130045978-A1 INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME ABBVIE INC. 2013-02-21 US disclosed
US-8314270-B2 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme ABBOTT LABORATORIES (US) 2012-11-20 US disclosed
US-20110218214-A1 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme ABBOTT LABORATORIES (US) 2011-09-08 US disclosed
EP-2269977-A2 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme Abbott Laboratories (US) 2011-01-05 EP disclosed
US-7855308-B2 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme ABBOTT LABORATORIES (US) 2010-12-21 US disclosed
US-20090192198-A1 INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME ABBOTT LABORATORIES (US) 2009-07-30 US disclosed
US-20090131434-A1 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme ABBOTT LABORATORIES (US) 2009-05-21 US disclosed
US-7511175-B2 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme ABBOTT LABORATORIES (US) 2009-03-31 US disclosed
EP-1846363-A2 ADAMANTYL DERIVATIVES AS INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME ABBOTT LABORATORIES (US) 2007-10-24 EP disclosed
US-20060281773-A1 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme ABBVIE INC. 2006-12-14 US disclosed
WO-2006074244-A2 ADAMANTYL DERIVATIVES AS INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME ABBOTT LABORATORIES (US) 2006-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131434-A1 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885HSD11B2 3/4885TSHR 3244/4885
US-20110218214-A1 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885HSD11B2 3/4885TSHR 3244/4885
US-20060281773-A1 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885HSD11B2 3/4885TSHR 3244/4885
US-20150065508-A1 INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME HSD11B1, HSD11B2, HSD17B1 HSD11B1 1/4885HSD11B2 2/4885TSHR 2808/4885
US-20090192198-A1 INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME HSD11B1, HSD11B2, HSD17B1 HSD11B1 1/4885HSD11B2 2/4885TSHR 2808/4885
US-20130045978-A1 INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME HSD11B1, HSD11B2, HSD17B1 HSD11B1 1/4885HSD11B2 2/4885TSHR 2808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.